United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shared investment power exercised 9,500 stock options at an exercise price of $117.76 per share on October 16, 2026, acquiring 9,500 common shares and selling 9,500 resulting shares in 13 reported sales. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported post-exercise balance was 214,410 stock options.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options on October 15, 2026, at an exercise price of $117.76 per share, then sold the 9,500 resulting common shares in multiple trades. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The trust's reported post-transaction stock-option position was 223,910 options, which expire March 15, 2027.
United Therapeutics Corp. (UTHR) EVP & General Counsel Paul A. Mahon exercised options for 8,300 common shares on October 15, 2026, at an exercise price of $146.03 per share, then sold the 8,300 shares in six transactions at reported weighted-average prices from $541.6421 to $546.5608 per share. The exercise and sales were made under a pre-arranged 10b5-1 plan entered into August 11, 2025. After the exercise, his reported position was 30,940 stock options.
United Therapeutics (UTHR) reported that family trusts in which Chairperson & CEO Martine A. Rothblatt shares investment power exercised 9,500 stock options at an exercise price of $117.7600 per share on October 14, 2026, acquiring 9,500 common shares and selling 9,500 common shares in multiple transactions. Reported sale prices ranged from $526.0700 to $546.0000 per share. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported stock-option position after the transaction was 233,410 shares.
Paul Mahon, identified as an officer of United Therapeutics Corp, gave notice of a proposed sale of 8,300 common shares on October 15, 2026. The proposed sale has an aggregate market value of $4,517,709.09, and Morgan Stanley Smith Barney LLC is named as broker. The shares are listed as acquired from the issuer through a stock option exercise on October 15, 2026, with cash payment. The notice also lists six sales during the preceding three months, each involving 8,300 shares.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options at an exercise price of $117.76 per share on October 13, 2026, acquiring 9,500 common shares and selling 9,500 shares in ten transactions. Reported weighted-average sale prices ranged from $542.7569 to $551.4900 per share. The exercise and sales were under a pre-arranged 10b5-1 trading plan adopted by Rothblatt on November 7, 2025. The trust held 242,910 stock options following the exercise.
United Therapeutics Corporation (UTHR) entered into a settlement agreement with Liquidia Technologies on October 13, 2026. Liquidia agreed to pay UTHR $185 million within 30 Business Days of the Execution Date for damages from Yutrepia sales from June 2, 2025 through October 13, 2026, plus $145.4 million for damages from ongoing sales to PH-ILD patients beginning the day after the Execution Date. The latter is due in two $72.7 million installments on or before January 31, 2027 and April 30, 2027. UTHR agreed to pay Liquidia $10 million within 30 Business Days of the Execution Date.
Liquidia must deliver a letter of credit within 10 Business Days of the Execution Date, immediately cease PH-ILD promotion, and stop sales of the affected Yutrepia product once the FDA approves removal of PH-ILD from its label. The parties will seek dismissal with prejudice within 10 days after UTHR receives the $185 million payment. Releases take effect only after both one-time payments, the required Liquidia officer declaration following label approval, and dismissal of covered proceedings.
The Third Circuit’s October 7, 2026 decision affirmed summary judgment for UTHR on antitrust and state unfair-competition claims, reversed summary judgment for Sandoz on contract liability, vacated the $61.6 million damages award, and remanded contract and tortious-interference claims. Claims against Robert Roscigno individually are excluded; UTHR may continue its trade-secrets claims against him.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options on October 12, 2026, at a $117.76 exercise price, then sold the resulting 9,500 common shares. The exercise and sales were under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported option position after the exercise was 252,410 options.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported the exercise by a family trust of 9,500 stock options on October 9, 2026, at $117.76 per share, producing 9,500 common shares; the trust sold all 9,500 shares in multiple trades. The exercise and sales were under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. The reported stock-option position following the exercise was 261,910 options.
At United Therapeutics (UTHR), Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shares investment power exercised 9,500 stock options at $117.76 per share on October 8, 2026, acquiring 9,500 common shares. The trust sold 9,500 common shares that day in multiple trades at reported prices ranging from $525.4958 to $541.2300 per share. The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported stock-option position afterward was 271,410 shares.